サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1212649

線維筋痛症治療薬の世界市場 2023

Fibromyalgia Therapeutics
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 263 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
線維筋痛症治療薬の世界市場 2023
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 263 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

線維筋痛症治療薬の世界市場は2030年までに38億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に30億米ドルと推定される線維筋痛症治療薬の世界市場は、2030年までに38億米ドルの修正規模に達し、分析期間2022-2030年に3%のCAGRで成長すると予測されます。本レポートで分析したセグメントの1つである抗てんかん薬は、CAGR2.8%を記録し、分析期間終了時には21億米ドルに達すると予測されます。パンデミック後の回復を考慮し、抗うつ薬分野の成長率は、今後8年間のCAGRを3.4%に修正しました。

米国市場は8億960万米ドル、中国はCAGR5%の成長を予測

米国の線維筋痛症治療薬市場は、2022年に8億960万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてCAGR5%で推移し、2030年までに7億3620万米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ1.7％と2.5％の成長が予測されています。欧州では、ドイツがCAGR約2％で成長すると予測されています。アジア太平洋地域の市場は、オーストラリア、インド、韓国などの国々を中心に、2030年までに4億8,560万米ドルに達すると予測されています。

調査対象企業の例

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6917

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Fibromyalgia Therapeutics Market to Reach $3.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Fibromyalgia Therapeutics estimated at US$3 Billion in the year 2022, is projected to reach a revised size of US$3.8 Billion by 2030, growing at a CAGR of 3% over the analysis period 2022-2030. Antiepileptics, one of the segments analyzed in the report, is projected to record a 2.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Antidepressants segment is readjusted to a revised 3.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $809.6 Million, While China is Forecast to Grow at 5% CAGR

The Fibromyalgia Therapeutics market in the U.S. is estimated at US$809.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$736.2 Million by the year 2030 trailing a CAGR of 5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.7% and 2.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$485.6 Million by the year 2030.

Select Competitors (Total 22 Featured):

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Fibromyalgia Syndrome: A Prelude
    • Recent Market Activity
    • Fibromyalgia Therapeutics Market: A Nascent Sector
    • A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio
    • FDA Approved Fibromyalgia Drugs
    • IMC-1: A Revolutionary Combination Therapy
    • Daiichi Sankyo's Mirogabalin Drug Improvises on Lyrica
    • Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine
    • Understanding Heightened Effect of Pain in Women Due to Fibromyalgia
    • Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses
    • Fibromyalgia Treatment through High-Pressure Oxygen Application
    • EU approves New Device to Treat Fibromyalgia and Migraine
    • Fibromyalgia Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Allergan plc (Ireland)
    • Boehringer Ingelheim GmbH (Germany)
    • Daiichi Sankyo Company Limited (Japan)
    • Eli Lilly and Company (USA)
    • Innovative Med Concepts, Inc. (USA)
    • Pfizer, Inc. (USA)
    • Pierre Fabre Medicament (France)
    • SWITCHBIOTECH LLC (USA)
    • Zynerba Pharmaceuticals, Inc. (USA)
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Antiepileptics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 13: World Fibromyalgia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 16: USA 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 19: Canada 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • JAPAN
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 22: Japan 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • CHINA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 25: China 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • EUROPE
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 28: Europe 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: Europe 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • FRANCE
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: France 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • GERMANY
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: Germany 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: Italy 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: UK 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: Spain 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: Russia 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: Rest of Europe 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Asia-Pacific 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: Asia-Pacific 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • AUSTRALIA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 61: Australia 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • INDIA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 64: India 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 67: South Korea 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • LATIN AMERICA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 73: Latin America 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 76: Latin America 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 79: Argentina 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 82: Brazil 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 85: Mexico 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 88: Rest of Latin America 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • MIDDLE EAST
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 91: Middle East 18-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 94: Middle East 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 97: Iran 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 100: Israel 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 103: Saudi Arabia 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 106: UAE 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 109: Rest of Middle East 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030
  • AFRICA
    • Fibromyalgia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 112: Africa 18-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2023 & 2030

IV. COMPETITION